Evolving paradigm in the management of allergic rhinitis-associated ocular symptoms: role of intranasal corticosteroids

References

• Gregory C, Cifaldi M, Tanner LA. Targeted intervention programs: creating a customized practice model to improve the treatment of allergic rhinitis in a managed care population. Am J Manag Care 1999;5:485–96
   Google Scholar
• Strachan D, Sibbald B, Weiland S, et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997;8:161–76
   PubMed Web of Science ®Google Scholar
• Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001;108:S2–S8
   PubMed Web of Science ®Google Scholar
• Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology [American Academy of Allergy, Asthma, and Immunology]. Ann Allergy Asthma Immunol 1998;81:478–518
   PubMed Web of Science ®Google Scholar
• Singh K, Bielory L [poster 34]. Poster presented at the American College of Allergy, Asthma & Immunology. Philadelphia, PA. November 10–15, 2006
   Google Scholar
• Allergies in America. Executive summary. Available at: www.myallergiesinamerica.com/news/overview.aspx [last accessed 29 March 2007]
   Google Scholar
• Lehman JM, Blaiss MS. Selecting the optimal oral antihistamine for patients with allergic rhinitis. Drugs 2006;66:2309–19
   PubMed Web of Science ®Google Scholar
• Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006;117:158–62
   PubMed Web of Science ®Google Scholar
• Keslin MH, Jarrell CM, Gregory C. Diagnosis and treatment of allergic rhinitis: primary care in an integrated health system setting. Am J Manag Care 1999;5(Suppl):S249–S256
   Google Scholar
• Bielory L. Role of antihistamines in ocular allergy. Am J Med 2002;113(Suppl 9A):34S–37S
   Google Scholar
• Klein B, Schmit-Eilenberger V, Schwalbe C, et al. Assessing the impact of eye allergy symptoms using the Eye Allergy Patient Impact Questionnaire (EAPIQ). Poster presentation at Deutsche Ophthalmologische Gesellscaft. Berlin. September 23–26, 2004
   Google Scholar
• Buchholz PM, Wlat J, Lorenz D, et al. Patient impact of allergic conjunctivitis as measured by the Eye Allergy Patient Impact Questionnaire (EAPIQ). Poster presented at the Association for Research in Vision and Ophthalmology. Fort Lauderdale, Florida. May 7, 2003
   Google Scholar
• Van Hoecke H, Vastesaeger N, Dewulf L, et al. Classification and management of allergic rhinitis patients in general practice during pollen season. Allergy 2006;61:705–11
   PubMed Web of Science ®Google Scholar
• Bousquet J, Annesi-Masesano I, Carat J, et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy 2005;35:728–32
   PubMed Web of Science ®Google Scholar
• Butrus S, Portela R. Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am 2005;18:485–92
   PubMedGoogle Scholar
• Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl 5):S147–S334
   Google Scholar
• Goodwin D. Management of ocular allergies. Pacific Optometry Continuing Education, 2006. Available at: www.opt.pacificu.edu/ce/catalog/16627-AS/16627-AS.html [last accessed 21 May 2007]
   Google Scholar
• Bremond-Gignac D. The clinical spectrum of ocular allergy. Curr Allergy Asthma Rep 2002;2:321–4
   PubMedGoogle Scholar
• van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000;30:891–99
   PubMed Web of Science ®Google Scholar
• Pitt AD, Smith AF, Lindsell L, et al. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 2004;11:17–33
   PubMed Web of Science ®Google Scholar
• Smith AF, Pitt AD, Rodruiguez AE, et al. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol 2005;12:233–42
   PubMed Web of Science ®Google Scholar
• Alexander M, Berger W, Buchholz P, et al. The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ). Health Qual Life Outcomes 2005;3:67
   PubMedGoogle Scholar
• Stempel DA, Woolf R. The cost of treating allergic rhinitis. Curr Allergy Asthma Rep 2002;2:223–30
   PubMedGoogle Scholar
• Bielory L. Allergic diseases of the eye. Med Clin North Am 2006;90:129–48
   PubMed Web of Science ®Google Scholar
• Bonini S. Allergic conjunctivitis: the forgotten disease. Chem Immunol Allergy 2006;91:110–20
   PubMedGoogle Scholar
• Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65:215–28
   Google Scholar
• Bonini S, Bonini S, Massimo B, et al. Allergen dose response and late symptoms in a human model of ocular allergy. J Allergy Clin Immunol 1990;96:869–76
   Google Scholar
• Bonini S, Bonini S, Vecchione A, et al. Inflammatory changes in conjunctival scrapings after allergen provocation in humans. J Allergy Clin Immunol 1988;82:462–9
   PubMed Web of Science ®Google Scholar
• Morrow GL, Abbott RL. Conjunctivitis. American Family Physician. February 15, 1998. Available at: www.aafp.org/afp/980215ap/morrow.html [last accessed 21 May 2007]
   Google Scholar
• Allergy drugs. Review of Optometry. June 15, 2006. Available at: www.revoptom.com/drugguide/pdf/article6.pdf [last accessed 4 May 2007]
   Google Scholar
• Sheppard J. Getting allergy symptoms under control. Ophthalmology Management. June 2002. Available at: www.ophthalmologymanagement.com/article.aspx?article=85402 [last accessed 4 May 2007]
   Google Scholar
• Price D, Bond C, Bouchard J, et al. International Primary Care Respiratory Group (IPCRG) guidelines: management of allergic rhinitis. Prim Care Respir J 2006;15:58–70
   PubMedGoogle Scholar
• Bielory L. Update on ocular allergy treatment. Expert Opin Pharmacother 2002;3:541–53
   PubMedGoogle Scholar
• Lieberman PL, Settipane RA. Azelastine nasal spray: a review of pharmacology and clinical efficacy in allergic and nonallergic rhinitis. Allergy Asthma Proc 2003;24:95–105
   PubMed Web of Science ®Google Scholar
• Indiana University School of Optometry Continuing Education. Treatment for allergic conjunctivitis. March 2007. Available at: www.opt.indiana.edu/ce/allergy/tx/htm [last accessed 3 June 2007]
   Google Scholar
• Dockhorn RJ, Duckett TG. Comparison of Naphcon-A and its components (naphazoline and pheniramine) in a provocative model of allergic conjunctivitis. Curr Eye Res 1994;13:319–24
   PubMed Web of Science ®Google Scholar
• Owen CG, Shah A, Henshaw K, et al. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. Br J Gen Pract 2004;54:451–6
   PubMed Web of Science ®Google Scholar
• Abelson MB, Gomes PJ, Pasquine T, et al. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. Allergy Asthma Proc 2007;28:427–33
   PubMed Web of Science ®Google Scholar
• Abelson MB, Gomes P, Crampton HJ, et al. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther 2004;26:35–47
   PubMed Web of Science ®Google Scholar
• Crampton JH. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double masked, placebo- and active-controlled trial. Clin Ther 2003;25:1975–87
   PubMed Web of Science ®Google Scholar
• Abelson MB, Greiner JV. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. Curr Med Res Opin 2004;20:1953–8
   Google Scholar
• Katelaris CH, Ciprandi G, Missotten L, et al., for the International Olopatadine Study Group. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther 2002;24:1561–75
   Google Scholar
• Butrus S, Greiner JV, Discepola M, Finegold I. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 2000;22:1462–72
   Google Scholar
• Greiner JV, Minno G. A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model. Clin Ther 2003;25:1988–2005
   PubMed Web of Science ®Google Scholar
• Deschenes J, Discepola M, Abelson M. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol Scand 1999;228(Suppl):47–52
   Google Scholar
• Berdy GJ, Stoppel JO, Epstein AB. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. Clin Ther 2002;24: 918–29
   Google Scholar
• James IG, Campbell LM, Harrison JM, et al. Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. Curr Med Res Opin 2003;19:313–20
   PubMed Web of Science ®Google Scholar
• Alexander M, Allegro S, Hicks A. Efficacy and acceptability of nedocromil sodium 2% and olopatadine hydrochloride 0.1% in perennial allergic conjunctivitis. Adv Ther 2000;17: 140–7
   Google Scholar
• Ballas Z, Blumenthal M, Tinkelman DG, et al. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38(Suppl):141–8
   Google Scholar
• Ciprandi G, Buscaglia S, Pesce GP, et al. Protective effect of loratadine on specific conjunctival provocation test. Int Arch Allergy Immunol 1991;96:344–7
   Web of Science ®Google Scholar
• Meltzer EO, Prenner BM, Nayak A, et al. Efficacy and tolerability of once-daily 5 mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis. Clin Drug Invest 2001;21:25–32
   Web of Science ®Google Scholar
• Simons FE, Prenner BM, Finn A Jr. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis: Desloratadine Study Group. J Allergy Clin Immunol 2003;111:617–22
   Google Scholar
• Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995;95:612–21
   PubMed Web of Science ®Google Scholar
• Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003;111:S835–S842
   PubMed Web of Science ®Google Scholar
• Nevius JM, Abelson MB, Welch D. The ocular drying effect of oral antihistamines (loratadine) in the normal population: an evaluation. Invest Ophthalmol Vis Sci 1999;40(Suppl):S549
   Google Scholar
• Simons FE, Simons KJ. Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. J Allergy Clin Immunol 2005;116:355–61
   PubMed Web of Science ®Google Scholar
• Verster JC, Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol 2004;92:294–303
   PubMed Web of Science ®Google Scholar
• Vuurman EF, Rikken GH, Muntjewerff ND, et al. Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur J Clin Pharmacol 2004;60:307–13
   PubMed Web of Science ®Google Scholar
• Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf 2003;26:863–93
   PubMed Web of Science ®Google Scholar
• Storms WW, Pearlman DS, Chervinsky P, et al. Effectiveness of azelastine nasal solution in seasonal allergic rhinitis. Ear Nose Throat J 1994;73:382–94
   PubMedGoogle Scholar
• LaForce C, Dockhorn RJ, Prenner BM, et al. Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. Ann Allergy Asthma Immunol 1996;76:181–8
   PubMed Web of Science ®Google Scholar
• Charpin D, Godard P, Garay RP, et al. A multicenter clinical study of the efficacy and tolerability of azelastine nasal spray in the treatment of seasonal allergic rhinitis: a comparison with oral cetirizine. Eur Arch Otorhinolaryngol 1995;252:455–8
   PubMed Web of Science ®Google Scholar
• Berlin JM, Golden SJ, Teets S, et al. Efficacy of a steroid nasal spray compared with an antihistamine nasal spray in the treatment of perennial allergic rhinitis. J Am Osteopath Assoc 2000;100(Suppl):S8–S13
   Google Scholar
• Baroody FM, Foster K, Markarian A, et al. Nasal ocular reflexes occur after nasal challenge with allergen. J Allergy Clin Immunol 2007;119:S162
   Google Scholar
• DeWester J, Philpot EE, Westlund RE, et al. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc 2003;24:331–7
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Levy AL, Hampel FC, et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 2004;34:952–7
   PubMed Web of Science ®Google Scholar
• Corren J. Intranasal corticosteroids for allergic rhinitis: how do different agents compare? J Allergy Clin Immunol 1999;104:S144–S149
   Google Scholar
• Gradman J, Caldwell M, Wolthers O, et al. Knemometric assessment of short-term lower-leg growth in children with allergic rhinitis (AR) treated with fluticasone furoate (FF) nasal spray. J Allergy Clin Immunol 2007;119:S304
   Web of Science ®Google Scholar
• Rhinocort Aqua (budesonide) prescribing information. Wilmington (DE): Astra Zeneca LP; January 2005
   Google Scholar
• Nasarel (flunisolide) nasal spray prescribing information. Available at: www.drugs.com/pro/nasarel/html [last accessed 31 May 2007]
   Google Scholar
• Nasonex (mometasone furoate monohydrate) nasal spray prescribing information. Kenilworth (NJ): Schering Corporation; September 2005
   Google Scholar
• Nasacort AQ (triamcinolone acetonide) nasal spray prescribing information. Bridgewater (NJ): sanofi-aventis US, LLC; September 2006
   Google Scholar
• Flonase (fluticasone propionate) nasal spray prescribing information. Research Triangle Park (NC): GlaxoSmithKline; March 2004
   Google Scholar
• Veramyst (fluticasone furoate) nasal spray prescribing information. Research Triangle Park (NC): GlaxoSmithKline; April 2007
   Google Scholar
• Tinkelman D, Falliers C, Gross G, et al. Multicenter evaluation of triamcinolone acetonide nasal aerosol in the treatment of adult patients with seasonal allergic rhinitis. Ann Allergy 1990;64:234–40
   PubMedGoogle Scholar
• Settipane G, Korenblat PE, Winder J, et al. Triamcinolone acetonide aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: a placebo-controlled, double-blind study. Clin Ther 1995;17:252–63
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Canonica WG, Grosclaude M, et al. Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy 2002;57:586–91
   PubMed Web of Science ®Google Scholar
• Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007;119:1430–7
   PubMed Web of Science ®Google Scholar
• Hebert J, Gates D, Danzig M. Mometasone furoate nasal spray improves total ocular symptom score in subjects with seasonal allergic rhinitis. J Allergy Clin Immunol 2007;119(Suppl 1):S61
   Google Scholar
• Anolik R, Pearlman D, Danzig M, Gates D. Mometasone furoate nasal spray improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescent subjects. J Allergy Clin Immunol 2007;119(Suppl 1):S61
   Google Scholar
• Bielory L, Danzig MR, Gates D. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Asthma Allergy Immunol [in press]
   Google Scholar
• Schenkel E, LaForce C, Gates D. Mometasone furoate nasal spray in seasonal allergic rhinitis. Allergy Clin Immunol Int 2007;19:50–3
   Google Scholar
• Martin BG, Ratner PH, Hampel FC, et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007;28:216–25
   PubMed Web of Science ®Google Scholar
• Ratner PH, Wingerzahn MA, van Bavel JH, et al. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2006;118:1142–8
   PubMed Web of Science ®Google Scholar
• Anolik R, Danzig M, Gates D. Efficacy of intranasal mometasone furoate in alleviating the ocular symptoms of seasonal allergic rhinitis. Poster presented at: XXVI Congress of the European Academy of Allergology and Clinical Immunology; June 9–13, 2007; Göteborg, Sweden
   Google Scholar
• Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. Br Med J 1998;317: 1624–9
   Google Scholar
• Robinson AC, Cherry JR, Daly S. Double-blind cross-over trial comparing beclomethasone dipropionate and terfenadine in perennial rhinitis. Clin Exp Allergy 1989;19:569–73
   Google Scholar
• Brooks CD, Francom SF, Peel BG, et al. Spectrum of seasonal allergic rhinitis symptom relief with topical corticoid and oral antihistamine given singly or in combination. Am J Rhinol 1996;10:193–9
   Google Scholar
• Bronsky EA, Dockhorn RJ, Meltzer EO, et al. Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97:915–21
   PubMed Web of Science ®Google Scholar
• Bunnag C, Jareoncharsri P, Wong EC. A double-blind comparison of nasal budesonide and oral astemizole for the treatment of perennial rhinitis. Allergy 1992;47:313–7
   Google Scholar
• Schoenwetter W, Lim J. Comparison of intranasal triamcinolone acetonide with oral loratadine for the treatment of patients with seasonal allergic rhinitis. Clin Ther 1995;17:479–92
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Creticos PS, Busse WW, et al. Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1996;97:749–55
   PubMed Web of Science ®Google Scholar
• Darnell R, Pecoud A, Richards DH. A double-blind comparison of fluticasone propionate aqueous nasal spray, terfenadine tablets and placebo in the treatment of patients with seasonal allergic rhinitis to grass pollen. Clin Exp Allergy 1994;24:1144–50
   Google Scholar
• Simpson RJ. Budesonide and terfenadine, separately and in combination, in the treatment of hay fever. Ann Allergy 1994;73:497–502
   PubMedGoogle Scholar
• Juniper EF, Kline PA, Hargreave FE, Dolovich J. Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 1989;83:627–33
   PubMed Web of Science ®Google Scholar
• Wood SF. Oral antihistamine or nasal steroid in hay fever: a double-blind double-dummy comparative study of once daily oral astemizole vs. twice daily nasal beclomethasone dipropionate. Clin Allergy 1986;16:195–201
   Google Scholar
• Beswick KBJ, Kenyon GS, Cherry JR. A comparative study of beclomethasone dipropionate aqueous nasal spray with terfenadine tablets in seasonal allergic rhinitis. Curr Med Res Opin 1985;9:560–7
   Google Scholar
• Gawchik SM, Lim J. Comparison of intranasal triamcinolone acetonide with oral loratadine in the treatment of seasonal ragweed-induced allergic rhinitis. Am J Manag Care 1997;3:1052–8
   PubMed Web of Science ®Google Scholar
• Condemi J, Schulz R, Lim J. Triamcinolone acetonide aqueous nasal spray versus loratadine in seasonal allergic rhinitis: efficacy and quality of life. Ann Allergy Asthma Immunol 2000;84:533–8
   Google Scholar
• Yáñez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002;89: 479–84
   Google Scholar
• Newson-Smith G, Powell M, Baehre M, et al. A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis. Eur Arch Otorhinolaryngol 1997;254:236–41
   Google Scholar
• Ortolani C, Foresi A, DiLorenzo G, et al. A double-blind, placebo-controlled comparison of treatment with fluticasone propionate and levocabastine in patients with seasonal allergic rhinitis [FLNCO2 Italian Study Group]. Allergy 1999;54:1173–80
   PubMed Web of Science ®Google Scholar
• Svensson C, Andersson M, Greiff L, et al. Effects of topical budesonide and levocabastine on nasal symptoms and plasma exudation responses in seasonal allergic rhinitis. Allergy 1998;53:367–74
   PubMed Web of Science ®Google Scholar
• Spangler DL, Abelson MB, Ober A, Gotnes PJ. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin Ther 2003;25:2245–67
   PubMed Web of Science ®Google Scholar
• Simpson K, Blair J. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000;59:301–21
   PubMed Web of Science ®Google Scholar
• Lanier BQ, Abelson MB, Berger WE, et al. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. Clin Ther 2002;24:1161–74
   PubMed Web of Science ®Google Scholar